{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.6152","upperLimit":"0.9979","value":"0.9167"},{"groupId":"OG001","lowerLimit":"0.6152","upperLimit":"0.9979","value":"0.9167"},{"groupId":"OG002","lowerLimit":"0.6152","upperLimit":"0.9979","value":"0.9167"},{"groupId":"OG003","lowerLimit":"0.6152","upperLimit":"0.9979","value":"0.9167"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"12"}],"units":"Participants"}],"title":"Overall"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.5175","upperLimit":"0.9972","value":"0.8889"},{"groupId":"OG001","lowerLimit":"0.5175","upperLimit":"0.9972","value":"0.8889"},{"groupId":"OG002","lowerLimit":"0.5175","upperLimit":"0.9972","value":"0.8889"},{"groupId":"OG003","lowerLimit":"0.5175","upperLimit":"0.9972","value":"0.8889"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"9"}],"units":"Participants"}],"title":"Multiple Myeloma"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.2924","upperLimit":"1.0000","value":"1.0000"},{"groupId":"OG001","lowerLimit":"0.2924","upperLimit":"1.0000","value":"1.0000"},{"groupId":"OG002","lowerLimit":"0.2924","upperLimit":"1.0000","value":"1.0000"},{"groupId":"OG003","lowerLimit":"0.2924","upperLimit":"1.0000","value":"1.0000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"}],"units":"Participants"}],"title":"Non-Hodgkin Lymphoma or Hodgkin Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"12"}],"units":"Participants"}],"description":"The secondary efficacy endpoint was the proportion of patients from whom a total number of CD34+ cells ≥2.5 x 10\\^6 cells/kg was collected within the first 4 leukapheresis sessions. Each patient's CD34+ cell number was calculated as the sum of CD34+ cell numbers collected from (up to) the first 4 leukapheresis sessions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Cumulative CD34+ cell counts ≥2.5 x 10\\^6 cells/kg within 1 leukapheresis session","id":"OG000","title":"Within 1 Leukapheresis Session"},{"description":"Cumulative CD34+ cell counts ≥2.5 x 10\\^6 cells/kg within 2 leukapheresis session","id":"OG001","title":"Within 2 Leukapheresis Sessions"},{"description":"Cumulative CD34+ cell counts ≥2.5 x 10\\^6 cells/kg within 3 leukapheresis session","id":"OG002","title":"Within 3 Leukapheresis Sessions"},{"description":"Cumulative CD34+ cell counts ≥5.0 x 10\\^6 cells/kg within 4 leukapheresis session","id":"OG003","title":"Within 4 Leukapheresis Sessions"}],"paramType":"NUMBER","populationDescription":"There were total 9 MM patients and 3 NHL or HD patients . A MM patient was treated with Revlimid, Following 2 leukapheresis sessions, a cumulative total of 0.18 x 10\\^6 cells/kg were collected. PI and Medical Monitor didn't feel that further leukapheresis sessions would achieve more cells, so the patient didn't have additional sessions.","reportingStatus":"POSTED","timeFrame":"Day 5 to Day 8","title":"Proportion of Patients From Whom a Total Number of CD34+ Cells ≥2.5 x 10^6 Cells/kg Was Collected Within the First 4 Leukapheresis Sessions","type":"SECONDARY","unitOfMeasure":"Proportion of patients"}